DNA topoisomerase II? and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer.

ABSTRACT: Cancer is essentially a genetic disease. Accumulated gene mutations accelerate genome instability, which eventually leads to uncontrollable growth of the tumor. Bladder cancer is the most common form of urinary tract cancer. This form of cancer has a poor prognosis due to its clinical heterogeneity and molecular diversity. Despite recent scientific advances, the knowledge and treatment of bladder cancer still lags behind that of other types of solid tumor. In the present study, available large data portals and other studies were used to obtain clinically relevant information, and the data were systematically processed to decipher the genes associated with bladder cancer. Genes associated with the survival time of patients with bladder cancer were successfully identified. The genes were enriched in common biological processes and pathways, and upregulated in tumor samples from patients. Among the top genes identified as associated with good or poor survival in bladder cancer, DNA topoisomerase II? (TOP2?) and RAD21 cohesin complex component (RAD21) were also increased in bladder cancer tissues and cell lines. Therefore, TOP2? and RAD21 could be used as potential therapeutic targets in bladder cancer.

SUBMITTER: Yu Z 

PROVIDER: S-EPMC6539755 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature